Thermo Fisher Scientific Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended April 1, 2023; comparative period ended April 2, 2022. Figures are unaudited. Thermo Fisher serves life sciences, analytical instruments, diagnostics, laboratory products and biopharma services markets.
Financial performance
- Revenue: $10.71 billion, down 9% year over year; organic revenue declined 8%. Product revenue was $6.40 billion (down from $8.02 billion), while service revenue grew to $4.31 billion from $3.80 billion.
- Profit and margins: GAAP operating income was $1.56 billion, down 45%, and operating margin was 14.6% versus 23.9%. Adjusted operating income was $2.33 billion, down 32%, with a 21.8% adjusted margin versus 29.2%. Net income attributable to Thermo Fisher was $1.29 billion versus $2.22 billion; diluted GAAP EPS was $3.32 versus $5.61, and adjusted EPS was $5.03 versus $7.25.
- Cash flow: Operating cash flow was $729 million versus $2.20 billion. Free cash flow, a non-GAAP measure, was $277 million versus $1.56 billion. Capital expenditures were $458 million.
- Liquidity and debt: Cash and cash equivalents were $3.48 billion at quarter-end, down from $8.52 billion at year-end 2022. The MD&A reports total debt of $35.26 billion; the debt note reports borrowings at carrying value of $35.05 billion. Short-term debt was $6.12 billion. The $5.00 billion revolving facility had no borrowings outstanding, and the company reported covenant compliance.
- Other: GAAP income tax provision was $46 million, a 3.4% effective rate, including a $144 million benefit from an intra-entity transaction. Net interest expense increased to $154 million from $118 million.
Changes and segment trends
- COVID-related product sales fell to $141 million from $1.68 billion, driving much of the consolidated decline and lower margins. Management also cited unfavorable mix and strategic growth investments; strong pricing and productivity provided partial offsets.
- Life Sciences Solutions: Revenue $2.61 billion, down 38%; segment income $836 million versus $2.18 billion, primarily reflecting lower COVID-related demand.
- Analytical Instruments: Revenue $1.72 billion, up 14%; segment income $421 million versus $301 million, supported by broad demand and productivity.
- Specialty Diagnostics: Revenue $1.11 billion, down 25%; segment income $280 million versus $353 million. The Binding Site acquisition contributed 4 percentage points to reported revenue change.
- Laboratory Products and Biopharma Services: Revenue $5.76 billion, up 6%; segment income $793 million versus $620 million, driven by pharma services and clinical research.
- The company acquired The Binding Site on January 3 for a net purchase price of $2.70 billion, funded with cash and settled debt.
Outlook, risks and unusual items
- No consolidated revenue or EPS guidance is stated in the supplied filing text. Management expected 2023 GAAP tax rate of 6%–8%, adjusted tax rate of approximately 11%, cash taxes of approximately $1.40 billion, and capital expenditures of approximately $2.0 billion net of disposals.
- The company identified approximately $125 million of additional restructuring charges, primarily in 2023, and expects to identify further actions. Q1 restructuring and other costs were $112 million, including asset impairments, pre-acquisition matters, headcount reductions and facility consolidations.
- Management said COVID-related demand for testing, therapies and vaccines was expected to continue declining in 2023, at much lower levels. It cited general economic conditions, customer and government spending, currency fluctuations, regulation, technology change, catastrophic events, and acquisition integration/benefit realization among risks.
- Operating cash flow was affected by working-capital movements, including $1.32 billion of cash use from changes in other assets and liabilities, primarily payment timing for compensation and income taxes. Investing cash use included the Binding Site acquisition; financing included $3.00 billion of share repurchases and $117 million of dividends paid.
- Environmental remediation, litigation, product liability and personal injury matters remain contingencies. The company reported no material changes to disclosed accruals, but said unfavorable outcomes or changes in remediation requirements could materially affect results, financial position or cash flows.
Key facts for investors to verify
- Whether core demand and margins stabilize as COVID-related sales decline, particularly in Life Sciences Solutions and Specialty Diagnostics.
- How working capital, acquisition spending and share repurchases affect cash generation and the company’s cash and debt balances.
- Integration and final purchase-price allocation for The Binding Site, including acquired intangible assets and related deferred taxes.
- Actual 2023 tax rate, cash taxes, capital expenditures and additional restructuring charges versus management’s stated expectations.
- Developments in litigation, environmental remediation and other contingencies, and any resulting changes to accruals or cash requirements.